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Abstract
Background: Everolimus -eluting stent (EES) is common used in patients undergoing percutaneous coronary
interventions (PCI). Our purpose is to evaluate long-term clinical outcomes of everolimus -eluting stent (EES) versus
paclitaxel-eluting stent (PES) in patients undergoing percutaneous coronaryinterventions (PCI) in randomized
controlled trials (RCTs).
Methods: We searched Medline, EMBASE, Cochrane Library, CNKI, VIP and relevant websites (https://scholar-google-
com.ezproxy.lib.usf.edu/) for articles to compare outcomes between everolimus-eluting stent and paclitaxel-eluting
stent without language or date restriction. RCTs that compared the use of everolimus -eluting stent and paclitaxel-eluting
stent in PCI were included. Variables relating to patient, study characteristics, and clinical endpoints were extracted.
Meta-analysis was performed using RevMan 5.2 software.
Results: We identified 6 published studies (from three randomized trials) more on everolimus-eluting stent (n = 3352)
than paclitaxel-eluting (n = 1639), with follow-up duration ranging from 3, 4 and 5 years. Three-year outcomes
of everolimus-eluting stent compared to paclitaxel-eluting were as following: the everolimus-eluting stent significantly
reduced all-cause death (relative risk [RR]:0.63; 95 % confidence interval [CI]: 0.46. to 0.82), MACE (RR: 0.56; 95 % CI: 0.41
to 0.77), MI (RR: 0.64; 95 % CI: 0.48 to 0.86), TLR (RR: 0.72; 95 % CI: 0.59 to 0.88), ID-TLR (RR: 0.74; 95 % CI: 0.59 to 0.92)
and ST (RR: 0.54; 95 % CI: 0.32 to 0.90). There was no difference in TVR between the everolimus-eluting and
paclitaxel-eluting (RR: 0.76; 95 % CI: 0.58 to 1.10); Four-year outcomes of everolimus-eluting compared to
paclitaxel-eluting: the everolimus-eluting significantly reduced MACE (RR: 0.44; 95 % CI: 0.18 to 0.98) and ID-TLR
(RR: 0.47; 95 % CI: 0.23 to 0.97). There was no difference in MI (RR: 0.48; 95 % CI: 0.16 to 1.46), TLR (RR: 0.46; 95 % CI: 0.20
to1.04) and ST ((RR: 0.34; 95 % CI: 0.05 to 2.39). Five-year outcomes of everolimus-eluting stent compared to
paclitaxel-eluting: There was no difference in ID-TLR (RR: 0.67; 95 % CI: 0.45 to 1.02) and ST (RR: 0.71; 95 %
CI: 0.28 to1.80).
Conclusions: In the present meta-analysis, everolimus-eluting appeared to be safe and clinically effective in
patients undergoing PCI in comparison to PES in 3-year clinical outcomes; there was similar no difference in
reduction of ST between EES and PES in long-term(≥4 years) clinical follow-ups. Everolimus-eluting is more safety
than paclitaxel-eluting in long-term clinical follow-ups, whether these effects can be applied to different patient
subgroups warrants further investigation.
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Background
Acute coronary syndrome (ACS) is a major public health
concern worldwide. Coronary artery disease is a leading
cause of morbidity and mortality in adults around the
world, and accounts for an even higher proportion of
deaths in developed countries. The WHO estimates that
7.3 million people died of coronary heart disease in
2008. Moreover, the number of people who die from car-
diovascular diseases, mainly from heart disease and stroke,
will increase and accounts for 23.3 million by the year of
2030 [1, 2]. Furthermore, ACS bears a heavy economic
burden for government and society in developed countries
[3, 4], which has also drawn attention of the experts in
developing countries due to the increased risk factors of
cardiovascular disease, including the prevalence of hyper-
cholesterolemia [5] and more smokers [6] etc.
Currently, percutaneous coronary intervention (PCI) is
another important means of reperfusion therapy in treat-
ment of patients with ACS, especially for patients with
ST-segment elevation myocardial infarction (STEMI),
with the additional drug therapies such as antiplatelet
drugs, anticoagulants, stains and thrombolytic therapy
etc. [7]. Compared with thrombolytic therapy, PCI is
more effective in restoring coronary blood flow. Numer-
ous studies, including a large meta-analysis showed that
PCI have shown the superiority in reducing mortality,
recurrent myocardial infarction and stroke compared
with thrombolytic therapy while the lower risk of bleed-
ing caused by PCI. Therefore, reperfusion therapy is
regarded as the standards and is recommended for
patients with STEMI [8].
Stents become more and more popular used to PCI.
Since the advent of the first use of stents—Palmaz
stents in the last century [9], bare metal stents (BMS)
were widely used in balloon angioplasty which was
the most popular method of treating heart disease
and was recommended by the American Medical
Association as the standard treatment [10]. But a
long-term study for patients who received a single
Palmaz stents showed that the incidence of restenosis
was 30.2 %, while the incidence ranged from 28 % to
41 % in patients who received angioplasty alone [11].
Arterial wall damage response mechanism triggered
by Balloon angioplasty and stenting, resulting in intimal
hyperplasia was an important cause of restenosis [10].
In order to reduce tissue proliferation, first-generation
drug-eluting stents (DES) were being designed and
coated with a polymer allowing controlled local deliv-
ery of a pharmaceutical agent with antineoplastic and
anti-inflammatory properties [12]. Now, recommenda-
tions of the European Society of Cardiology call for
the use of drug-eluting stents for PCI if the patient
has no contraindication to extended treatment with
dual-antiplatelet therapy [13].
Paclitaxel-eluting stent was one of the first-generation
drug eluting stents. Comparing with BMS, Paclitaxel-
Eluting Stent reduced the rates of restenosis significantly.
However, some studies have shown that some type of
stent thrombosis occurs [14], the two large researches in
first-generation DES showed that an annual rate of late
stent thrombosis was 0.4–0.6 % for up to 4 years after
stent implantation [15–17]. Thus, the second-generation
DES was designed to reduce the incidence of late stent
thrombosis and solve the problem of restenosis by re-
placing the coating drug.
Everolimus-eluting stent (EES) was a second gener-
ation DES approved by the FDA in July 2008 with its
cobalt chromium stent design, high deliverability, and
everolimus drug coating used to prevent abnormal tissue
growth [18]. Due to its lipophilic chemical structure, it is
more rapidly absorbed into the arterial wall, potentially
making it a better drug for local intravascular delivery
following stent implantation [19, 20]. The FUTURE
Trail, EXAMINATION Trail [21] and SPIRIT FIRST
Trail showed the EES to be safe, feasible, and efficient
[14, 22–26]. The studies showed the superiority of PES
to EES for short time [27–30]. Despite this, the long-
term efficacy of EES use should be investigated to reduce
the individual trails and the limitations of short-term
studies.
Similarly, the TAXUS trials assessed the safety and effi-
cacy of paclitaxel-eluting stent (PES) in the treatment of
coronary artery disease [31–34]. Large randomized clinical
trials such as SPIRIT Trail and COMPARE Trails designed
to compare EES with PES have shown reduced rates of re-
peat revascularization, major adverse cardiac events, myo-
cardial infarction and stent thrombosis [35–38]. Hence, it
is necessary to carry out a new meta-analysis including
RCTs only and to update the prior meta-analyses on the
basis of the preferred reporting items for systematic
reviews and meta-analysis (PRISMA) items [39].
A comprehensive network meta-analysis had dis-
played that cobalt-chromium everolimus eluting stents
(CoCr-EES) has the lowest rate of baremetal stents,
paclitaxel-eluting stents(PES), sirolimus-eluting stents,
phosphorylcholine-based zotarolimuseluting stentss-
tent thrombosis, and Resolute zotarolimus-eluting
stents within 2 years of implantation. However, the
study only inculed 6 stduies with one and 2 years fol-
low ups. The aim of this meta-analysis was to compare
the efficacy and safety of EES versus PES especially
with regards to the patient of all-cause death, major
adverse cardiac events, stent thrombus, and myocar-
dial infarction as primary outcomes, and of target le-
sion revascularization, ischemia-driven target lesion
revascularization, and target vessel revascularization
as secondary outcomes over long-term (followed up 3,
4 and 5 years), and to provide much more reliable
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No protocol has been registered in public, however draft
related to the study already exists.
Search strategy and selection criteria
We searched Medline, EMBASE, Cochrane Library, CNKI,
VIP, and relevant websites (https://scholar-google-com.
ezproxy.lib.usf.edu/) by two researchers (Min.M. and Bei.G.).
Disagreements were resolved by consensus. The reference
list of relevant studies was further scanned. No restrictions
of language, publication date or publication status were
imposed. The last search was run on October 2014.
The following search terms were used: “percutaneous
coronary intervention”, “randomized trial”, “everolimus-
eluting stent”, “Xience”, “drug-eluting stent”, “paclitaxel-
eluting stent” and “TAXUS”. To be included in this study,
the citation had to meet the following criteria: randomized
controlled trials that compared the use of EES and PES in
percutaneous coronary intervention (PCI). Exclusion cri-
teria were: (1) ongoing studies; (2) irretrievable data; (3)
Follow up duration of less than 3 years; (4) non random-
ized studies; (5) animal studies; (6) case reports; (7) related
reviews; (8) protocols; (9) conference abstracts. The Flow
Diagram was shown in Fig. 1.
Data extraction and risk of bias assessment
Two investigators (MENG.M. and GAO.B.) independently
included reports at title and/or at abstract level, disagree-
ment was resolved with a third reviewer (GE.B.), and stud-
ies that met inclusion criteria were selected for further
analysis. Furthermore, we e-mailed authors of trials for
supplemental data which were partially published.
Data extraction included:
1. General information: title, authors, publication date,
and article sources;
2. Study characteristics: subject characteristics,
purpose, sites, study period, comparability of
baseline, research results;
3. Primary Outcomes: major adverse cardiac events
(MACE), myocardial infarction (MI), cardiac
death, stent thrombus (ST); Secondary outcomes:
target lesion revascularization (TLR), target vessel
revascularization (TVR), all-cause death,,
ischemia-driven target lesion revascularization
(ID-TLR).
Quality of included studies was appraised by two inves-
tigators (M.M. and G.B.), and the assessment is shown in
Fig. 2. The risk of selection, performance, detection,
attrition, and reporting bias (expressed as low risk of bias,
high risk or unclear risk of bias, the underlying risk of bias
can’t be determined due to incomplete reporting) were
evaluated separately [41].
Data analysis
We used Review Manager (5.2) software for Meta analysis,
and calculated the relative risk (RR) from the abstracted
data. The average effects for the outcomes and 95 % confi-
dence intervals (CI) were obtained using a random effects
mode. Heterogeneity of RR across trials was assessed
using the Cochrane Q statistic (P value ≤ 0.05 was consid-
ered significant) and the I2 statistic.
For the primary endpoint, small-study effects were
analyzed by constructing a funnel plot, in which the stand-
ard error of the lnRR was plotted against RR for 3–5 years
follow ups as minimize the publication bias. The absence
of any asymmetric distribution suggested no publication




One thousand three hundred twenty articles were accessed
through searching, and 734 articles were retrieved after
duplicate were removed by Endnote X4 software, then
abstracts and full texts were reviewed again with excluding
duplicate papers and articles that do not meet the inclu-
sion criteria. Finally, six published studies [42–47] from 3
randomized controlled trials were included in the present
meta-analysis.
Characteristics of the included reviews
There were more patients randomized to EES (n = 3352)
than to PES (n = 1639), resulted from imbalanced
randomization in certain studies. The mean age
ranged from 62 to 65 years with the majority of pa-
tients being male. Diabetes were not excluded. The
frequency of diabetes mellitus ranged from 23.67 % to
32.14 %. Follow-up period ranged from 3.4 to 5 years.
General characteristics of the included studies are
shown in Table 1.
Results of meta-analysis
Three-year outcomes of EES compared to PES [42, 44, 45]
Primary outcomes
MACE SPIRIT IV Trail [45] did not publish the MACE
data of 3-year outcomes of EES compared to PES. There-
fore, the incidence of MAGE at all follow-ups was 9.10 %
(75 of 824) among patients treated with the EES and
16.31 % (61 of 374) among patients treated with the PES
(RR: 0.56, 95 % CI: 0.41–0.77; P < 0.05) [42, 44], with no
significant study heterogeneity (Chi2 = 0.43; P = 0.51;
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I2 = 0 %) (Fig. 4(a)). There was a statistically significant
difference between EES and PES.
MI The incidence of MI at all follow-ups was 3.14 %
(103 of 3282) among patients treated with the EES and
4.86 % (78 of 1603) among patients treated with the
PES (RR: 0.64, 95 % CI: 0.48–0.86; P < 0.05) [42, 44, 45],
with no significant study heterogeneity (Chi2 = 2.26;
P = 0.88; I2 = 0 %) (Fig. 4(b)). There was a statistically
significant difference between EES and PES.
All-cause death The incidence of all-cause death at all
follow-ups was 3.12 % (103 of 3297) among patients
treated with the EES and 5.02 % (81 of 1614) among
patients treated with the PES (RR: 0.63, 95 % CI: 0.46–
0.82; P < 0.05) [42, 44, 45], with no significant study
Fig. 1 Data source flow chart diagram
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heterogeneity (Chi2 = 0.38; P = 0.83; I2 = 0 %) (Fig. 4(c)).
There was a statistically significant difference between
EES and PES.
ST The Academic Research Consortium’s (ARC) con-
sensus definite/probable ST were totally included for
analysis. The incidence of all STs at all follow-ups was
0.73 % (24 of 3270) among patients treated with the EES
and 1.63 % (26 of 1596) among patients treated with the
PES (RR: 0.44, 95 % CI: 0.26–0.97; P < 0.05) [42, 44, 45],
with no significant study heterogeneity (Chi2 = 1.30; P =
0.52; I2 = 0 %) (Fig. 4(d)). There was a statistically signifi-
cant difference between EES and PES.
Secondary outcomes
TLR The incidence of TLR at all follow-ups was 6.46 %
(213 of 3297) among patients treated with the EES and
8.98 % (145 of 1614) among patients treated with the
PES (RR: 0.66, 95 % CI: 0.47–0.92; P < 0.05) [42, 44, 45],
with no significant study heterogeneity (Chi2 = 3.68; P =
0.16; I2 = 46 %) (Fig. 4(e)). There was a statistically sig-
nificant difference between EES and PES.
TVR The incidence of TVR at all follow-ups was 9.28 %
(306 of 3297) among patients treated with the EES and
10.90 % (176 of 1614) among patients treated with the
PES (RR: 0.82, 95 % CI: 0.57–1.19; P > 0.05) [42, 44, 45],
with a significant study heterogeneity (Chi2 = 5.59; P =
0.06; I2 = 64 %) (Fig. 4(f )). There was no statistically sig-
nificant difference between EES and PES.
ID-TLR The incidence of ID-TLR at all follow-ups was
5.68 % (187 of 3289) among patients treated with the EES
and 7.76 % (125 of 1610) among patients treated with the
PES (RR: 0.74, 95 % CI: 0.59–0.92; P < 0.05) [42, 44, 45],
with no significant study heterogeneity (Chi2 = 1.56; P =
0. 46; I2 = 0 %) (Fig. 4(g)). There was a statistically signifi-
cant difference between EES and PES.
Four-year outcomes of EES compared to PES [47]
In all included studies, only SPRIT II Trail reported 4-
year follow-up clinical outcomes. We extracted the data
of 4 year-end points and analyzed as following.
Primary outcomes
MACE The incidence of MAGE at all follow-ups was
7.62 % (15 of 195) among patients treated with the EES
and 16.42 % (11 of 67) among patients treated with the
PES (RR: 0.47, 95 % CI: 0.23–0.97; P < 0.05) [47]
(Fig. 5(a)). There was a statistically significant difference
between EES and PES.
MI The incidence of MI at all follow-ups was 3.59 %
(7 of 195) among patients treated with the EES and
7.46 % (5 of 67) among patients treated with the PES
(RR: 0.48, 95 % CI: 0.16–1.46; P > 0.05) [47] (Fig. 5(b)).
There was no statistically significant difference between
EES and PES.
ST The incidence of ST at all follow-ups was 1.02 %
(2 of 195) among patients treated with the EES and
2.98 % (2 of 67) among patients treated with the PES
(RR: 0.34, 95 % CI: 0.05–2.39; P > 0.05) [47] (Fig. 5(c)).
There was no statistically significant difference between
EES and PES.
Secondary outcomes
TLR The incidence of TLR at all follow-ups was 6.15 %
(12 of 195) among patients treated with the EES and
13.43 % (9 of 67) among patients treated with the PES
(RR: 0.46, 95 % CI: 0.20–1.04; P > 0.05) [47] (Fig. 5(d)).
There was no statistically significant difference between
EES and PES.
ID-TLR The incidence of ID-TLR at all follow-ups was
7.69 % (15 of 195) among patients treated with the EES
and 16.42 % (11 of 67) among patients treated with the
Fig. 2 Risk of bias graph
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Fig. 3 (See legend on next page.)
Meng et al. BMC Cardiovascular Disorders  (2016) 16:34 Page 6 of 11
PES (RR: 0.47, 95 % CI: 0.23–0.97; P < 0.05) [47] (Fig. 5(f)).
There was a statistically significant difference between
EES and PES.
Five-year outcomes of EES compared to PES [43, 46]
In all included studies, only SPRIT II, III and IV Trail re-
ported 4-year follow-up clinical outcomes, SPRIT III Trail
did not publish relevant data, so we extracted the reported
data of 5 year-end points and analyzed as following.
Primary outcomes
ST The incidence of definite/probable ARC ST at all
follow-ups was 1.30 % (11 of 844) among patients
treated with the EES and 1.86 % (7 of 377) among patients
treated with the PES (RR: 0.71, 95 % CI: 0.28–1.80; P >
0.05) [43, 46], with no significant study heterogeneity
(Chi2 = 0.66; P = 0.42; I2 = 0 %) (Fig. 6(a)). There was no
statistically significant difference between EES and PES.
Secondary outcomes
ID-TLR The incidence of ID-TLR at all follow-ups was
7.53 % (53 of 704) among patients treated with the EES
and 11.50 % (33 of 287) among patients treated with the
PES (RR: 0.67, 95 % CI: 0.45–1.02; P > 0.05) [43, 46],
with no significant study heterogeneity (Chi2 = 0.42; P =
0. 52; I2 = 0 %) (Fig. 6(b)). There was no statistically sig-
nificant difference between EES and PES.
Discussions
Characteristic and quality of included studies
For this meta-analysis, we screened 1320 articles, only 6
studies (three trails) [42–47] which met the inclusion
criteria were considered. The randomized trials in our
meta-analysis included patients with PCI, and two of
which described a method of generating randomness.
SPRIT Trails were all single-blinded, but it was not clear
whether allocation concealment was used, and reported
failing in follow-ups. Risk of bias graph is shown in Fig. 2.
SPIRIT Trails included a proportion of the diabetic
population, especially SPIRIT IV trail, which included
32.14 % diabetics [45]. The baseline characteristic of
SPRIT Trails were consistent, described safety of eluting
stent using the dangers of endpoints such as MACE, MI,
TLR,ID-TLR, instead of beneficial indicators, in order to
avoid biases in outcome evaluation.
Clinical significance of this meta-analysis
In recent years, drug-eluting stents have revolutionized
interventional cardiology and become an important part
of interventional cardiology. New stents through large
RCT trials has been verified to be effective, but it should
be a long-term follow-up of clinical indicators to evaluate
the difference of long-term efficacy and safety of new
stents and old stents. Meta-analysis and RCT trials
showed that EES could reduce dangerous endpoints, such
as MACE, MI, TLR, ID-TLR in ≤ 3 year follow-ups when
compared with PES.
The present meta-analysis of RCTs compared EES to
PES for PCI with clinical follow-ups from three to
5 years, using multiple endpoints. Based on results of
the 3-year clinical follow-up [42, 44, 45] combined data-
set, significant reductions with EES compared with PES
were observed for the safety endpoints of all-cause death
and MACE, MI, and ST, and improved efficacy with re-
ducing rates of TLR, ID-TLR, but similar rates in the
two groups of TVR. Only one trail (SPIRIT IV) [47] was
included for analyzing 4-year clinical follow-up results,
which demonstrated EES could reduce MACE and ID-
TLR, which is better than PES, but couldn’t reduce MI,
TLR and ST.
The main finding of our meta-analysis is that we dem-
onstrated EES was superior clinical efficacy to the PES
in the reduction of ID-TLR and ST by the four [47] and
5-year clinical follow-up [43, 46] combined dataset.
However, the differences were not statistically signifi-
cant. A meta-analysis reported by Ashraf Alazzoni [29]
demonstrated that EES was superior to PES in reducing
early (0–30 days), late (31–365 days), and very late ST
(>365 days) with statistically significant difference, but
the very late ST group had not to subgroup analysis. It
might imply a non-significant trend for reducing ST at a
very long term clinical follow up, and that might be
related to sample size problem.
Study limitations
First, the 3-year follow-up clinical trial [42, 44, 45] compar-
ing outcomes demonstrated that a consistent heterogeneity
was observed for the TVR endpoints(I2 ≥ 50 %), even when
Odds Ratio were used for analysis. A source of heterogen-
eity might be due to the reported inconsistency in patients’
number of TVR. for example, SPIRIT II Trail [42, 46, 47]
clearly illustrated all of TVR numbers included all the
numbers of TLR, but SPIRIT III [43, 44] and SPIRIT IV
Trail [46] did not clearly state whether the occurrence of
(See figure on previous page.)
Fig. 3 Funnel plot of primary outcomes included in the meta-analysis. The funnel plot of (a: 3-year MACE, b: 3-year MI, c: 3-year death, d: 3-year
ST, e: 4-year MACE, f: 4-year MI, g: 5-year ST). the standard error (SE) of the ln relative risk (RR) was plotted against the relative risk for (a:3-year
MACE, b: 3-year MI, c: 3-year death, d: 3-year ST, e: 4-year MACE, f: 4-year MI, g: 5-year ST) 3-year MACE. The absence of any asymmetric distribution
suggested no publication bias
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Table 1 Baseline of characteristics of the included trials
Source Number
of patents





































PES† 77 62 ± 9 61 20 59 ± 10 2.82 ± 0.58 13.2 ± 6.4
SPIRIT III
[48, 49]
EES* 669 63.2 ± 10.5 469 198 70.0 ± 13.3 2.77 ± 0.45 14.7 ± 5.6 1. Stable, unstable
angina;













TLRxx TVR§§ TLFllll 3.5 Abbott
vascular
PES† 332 62.8 ± 10.2 218 92 69.4 ± 13.6 2.76 ± 0.46 14.7 ± 5.7
SPIRIT
IV[50]
EES* 2460 63.3 ± 10.5 1664 787 72.3 ± 12.6 — — 1. Stable, unstable
angina;






















PES† 1230 63.3 ± 10.2 833 399 72.0 ± 12.8 — —
Abbreviations: *:everolimus-eluting stent; †:paclitaxel-eluting stent; ‡:myocardial infarction; xLVEF: left ventricular ejection fraction; §:left main; ll:major adverse cardiac events; #:ischemia-driven target lesion revascularization;














TVR number included all TLR patients. However, other
key indicators clearly demonstrated that EES had certain
superiority to PES by the 3-year clinical follow-up com-
bined dataset.
Second, Spirit Trails were all sponsored by Abbott
Vascular, therefore there might be a certain risk of re-
sults’ bias.
Third, this meta-analysis of RCT trials were from the
same series, due to the relatively limitation of probably
same inclusion standard and same researchers, there is a
certain risk of results’ bias for long-term efficacy and
safety with EES and PES. Therefore, we should include
outcomes data of Compare Trail for 3–5 years clinical
follow-up, in order to avoid results’ bias mentioned above.
Unfortunately, the relevant data of Compared Trail has
not been reported so far [37, 38].
Finally, limited databases were searched and only
published articles were included, as a result, there is
the possibility of no comprehensive trails. As clinical
significance of this meta-analysis might be uncertain,
larger sample size will be needed to collect, and higher
quality of research will be needed.
Future research directions
It has been reported that elderly, women and types of
vascular of Sprite III Trial were analyzed for evaluating a
Fig. 5 Risk Ratio of 4-year clinical outcomes: the Risk Ratio of a: MACE, b: MI; c: ST; d: TLR; e: ID-TLR) at 4-year follow-up associated with EES versus PES
Fig. 4 Risk Ratio of 3-year clinical outcomes: the Risk Ratio of (a: MACE, b: MI, c: all cause of death; d: ST; e: TLR, f: TVR, g: ID-TLR) at 3-year follow-up
associated with EES versus PES
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long term clinical endpoints [48, 49]. Considering the
bias of present study, it is recommended that future
large, randomized clinical trials for diabetic patients
should be carried out, and then diabetes will be included
for sub-analysis respectively in order to evaluate signifi-
cance safety of EES and PES in diabetes, which do not
continue to further at moment for few original research
data. The risk of stent fracture in EES has not been
assessed [50], therefore, further studies should focus on
that as well.
Conclusions
The current evidence showed that EES appeared to be
safe and clinically effective in patients undergoing PCI
comparing to PES in long-term clinical outcomes.
However, more randomized data are needed, especially
on 4-year follow-ups.
Role of the funding source
There was no funding source for this study. The corre-
sponding author had full access to all the data in the study
and had final responsibility for the decision to submit for
publication.
Abbreviations
EES: everolimus-eluting stent; PES: paclitaxel-eluting stent; PCI: percutaneous
coronary interventions; RCT: randomized controlled trial; RR: relative risk;
CI: confidence interval; ACS: acute coronary syndrome; BMS: bare metal
stents; DES: drug-eluting stents; MACE: major adverse cardiac events;
MI: myocardial infarction; TLR: target lesion revascularization; TVR: target
vessel revascularization; TLR: target lesion failure; ID-TLR: ischemia-driven
target lesion revascularization; ST: stent thrombus.
Competing interests
The authors declare that the research was conducted in the absence of any
commercial or financial relationships that could be construed as a potential
conflict of interests.
Authors’ contributions
Ge B and Meng M conceived of the study and its design. Gao B, Wang X
and Sa R N helped with the acquisition and preparation of data. Bai Z G, Ge
B and Meng M carried out the study, performed the statistical analysis, drafted,
and revised the manuscript. All authors read and approved the final manuscript.
Author details
1Department of Pharmacy, Gansu Provincial Hospital, Donggang West Road
No. 204, Lanzhou, Gansu 730000, China. 2Evidence-Based Medicine Center,
Lanzhou University, Lanzhou, Gansu 730000, China.
Received: 18 July 2015 Accepted: 29 January 2016
References
1. Mathers CD, Loncar D. Projections of global mortality and burden of disease
from 2002 to 2030. PLoS Med. 2006;3:e442.
2. Peterson MC, Syndergaard T, Bowler J, Doxey R. A systematic review of factors
predicting door to balloon time in ST-segment elevation myocardial infarction
treated with percutaneous intervention. Int J Cardiol. 2012;157:8–23.
3. Mantovani LG, Fornari C, Madotto F, et al. Burden of acute myocardial
infarction. Int J Cardiol. 2011;150:111–2.
4. Menzin J, Wygant G, Hauch O et al. One-year costs of ischemic heart
disease among patients with acute coronary syndromes: findings from a
multi-employer claims database*. Curr. Med. Res. Opin.® 2008; 24: 461–468.
5. Al-Lawati J, Sulaiman K, Panduranga P. The Epidemiology of Acute Coronary
Syndrome in Oman: Results from the Oman-RACE study. Sultan Qaboos
Univ Med J. 2013;13:43.
6. Hata J, Kiyohara Y. Epidemiology of Stroke and Coronary Artery Disease in
Asia. Circ. J. 2013;77:1923–1932.
7. Makki N, Brennan TM, Girotra S. Acute Coronary Syndrome. J Intensive Care Med.
2013;18:1–15.
8. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous
thrombolytic therapy for acute myocardial infarction: a quantitative review
of 23 randomised trials. Lancet. 2003;361:13–20.
9. Schatz RA, Palmaz J, Tio F, et al. Balloon-expandable intracoronary stents in
the adult dog. Circulation. 1987;76:450–7.
Fig. 6 Risk Ratio of 5-year clinical outcomes: the Risk Ratio of a: ST, b: ID-TLR) at 5-year follow-up associated with EES versus PES
Meng et al. BMC Cardiovascular Disorders  (2016) 16:34 Page 10 of 11
10. Puranik AS, Dawson ER, Peppas NA. Recent advances in drug eluting stents.
Int J Pharm. 2013;441:665–79.
11. Ellis SG, Savage M, Fischman D, et al. Restenosis after placement of
Palmaz-Schatz stents in native coronary arteries. Initial results of a
multicenter experience. Circulation. 1992;86:1836–44.
12. Claessen BE, Caixeta A, Henriques JP, Piek JJ. Current status of the Xience V®
everolimus-eluting coronary stent system. Expert Rev Cardiovasc Ther.
2010;8:1363–74.
13. Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization
the task force on myocardial revascularization of the european society of
cardiology (esc) and the european association for cardio-thoracic surgery
(eacts). Eur Heart J. 2010;31:2501–55.
14. Grube E, Silber S, Hauptmann KE, et al. TAXUS I six-and twelve-month results
from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent
for de novo coronary lesions. Circulation. 2003;107:38–42.
15. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary
stents after discontinuation of antiplatelet therapy. Lancet. 2004;364:1519–21.
16. Wenaweser P, Daemen J, Zwahlen M, et al. Incidence and correlates of
drug-eluting stent thrombosis in routine clinical practice4-year results from
a large 2-institutional cohort study. J Am Coll Cardiol. 2008;52:1134–40.
17. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent
thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine
clinical practice: data from a large two-institutional cohort study. Lancet.
2007;369:667–78.
18. Harris E. Industry Update: The latest developments in therapeutic delivery.
Ther Deliv. 2013;4:659–65.
19. Kahan BD, Wong RL, Carter C, et al. A Phase I Study of A 4-Week Course of
Sdz-Rad (Rad) in Quiescent Cyclosporine-Prednisone-Treated Renal Transplant
Recipients1, 2. Transplantation. 1999;68:1100–6.
20. Allocco DJ, Joshi AA, Dawkins KD. Everolimus-eluting stents: update on
current clinical studies. Medical Devices (Auckland, NZ). 2011;4:91.
21. Sabaté M, Brugaletta S, Cequier A, et al. The EXAMINATION (Everolimus-Eluting
Stents Versus Bare-Metal Stents in ST-Segment Elevation Myocardial Infarction)
Trial: 2-Year Results From a Multicenter Randomized Controlled Trial. J Am Coll
Cardiol Intv. 2013;7:64–71.
22. Costa RA, Lansky AJ, Mintz GS, et al. Angiographic results of the first human
experience with everolimus-eluting stents for the treatment of coronary
lesions (the FUTURE I trial). Am J Cardiol. 2005;95:113–6.
23. Grube E, Sonoda S, Ikeno F, et al. Six-and twelve-month results from first
human experience using everolimus-eluting stents with bioabsorbable
polymer. Circulation. 2004;109:2168–71.
24. Tsuchiya Y, Lansky AJ, Costa RA, et al. Effect of Everolimus-Eluting Stents in
Different Vessel Sizes (from the Pooled FUTURE I and II Trials). Am J Cardiol.
2006;98:464–9.
25. Serruys PW, Ong A, Piek JJ, et al. A randomized comparison of a durable
polymer Everolimus-eluting stent with a bare metal coronary stent: The
SPIRIT first trial. EuroIntervention. 2005;1:58–65.
26. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent
in patients with coronary artery disease. N Engl J Med. 2004;350:221–31.
27. Cassese S, Piccolo R, Galasso G, et al. Twelve-month clinical outcomes of
everolimus-eluting stent as compared to paclitaxel-and sirolimus-eluting
stent in patients undergoing percutaneous coronary interventions. A
meta-analysis of randomized clinical trials. Int J Cardiol. 2011;150:84–9.
28. Baber U, Mehran R, Sharma SK, et al. Impact of the Everolimus-Eluting Stent
on Stent ThrombosisA Meta-Analysis of 13 Randomized Trials. J Am Coll
Cardiol. 2011;58:1569–77.
29. Alazzoni A, Al-Saleh A, Jolly SS. Everolimus-eluting versus paclitaxel-eluting
stents in percutaneous coronary intervention: meta-analysis of randomized
trials. Thrombosis. 2012;2012:1–8.
30. Dangas GD, Serruys PW, Kereiakes DJ, et al. Meta-Analysis of Everolimus-Eluting
Versus Paclitaxel-Eluting Stents in Coronary Artery Disease Final 3-Year Results of
the SPIRIT Clinical Trials Program (Clinical Evaluation of the Xience V Everolimus
Eluting Coronary Stent System in the Treatment of Patients With De Novo
Native Coronary Artery Lesions). J Am Coll Cardiol Intv. 2013;6:914–22.
31. Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the
effectiveness of slow-and moderate-release polymer-based paclitaxel-eluting
stents for coronary artery lesions. Circulation. 2003;108:788–94.
32. Silber S, Colombo A, Banning AP, et al. Final 5-Year Results of the TAXUS II
Trial A Randomized Study to Assess the Effectiveness of Slow-and
Moderate-Release Polymer-Based Paclitaxel-Eluting Stents for De Novo
Coronary Artery Lesions. Circulation. 2009;120:1498–504.
33. Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymer-based
paclitaxel-eluting stent with a bare metal stent in patients with complex
coronary artery disease: a randomized controlled trial. JAMA. 2005;294:1215–23.
34. Tanabe K, Serruys PW, Grube E, et al. TAXUS III Trial In-stent restenosis
treated with stent-based delivery of paclitaxel incorporated in a slow-
release polymer formulation. Circulation. 2003;107:559–64.
35. Stone GW, Midei M, Newman W, et al. Comparison of an everolimus-eluting
stent and a paclitaxel-eluting stent in patients with coronary artery disease:
a randomized trial. JAMA. 2008;299:1903–13.
36. Planer D, Smits PC, Kereiakes DJ, et al. Comparison of Everolimus-and
Paclitaxel-Eluting Stents in Patients With Acute and Stable Coronary
SyndromesPooled Results From the SPIRIT (A Clinical Evaluation of the XIENCE
V Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of
Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary
Revascularization in Daily Practice) Trials. J Am Coll Cardiol Intv. 2011;4:1104–15.
37. Smits PC, Kedhi E, Royaards K-J, et al. 2-Year Follow-Up of a Randomized
Controlled Trial of Everolimus-and Paclitaxel-Eluting Stents for Coronary
Revascularization in Daily PracticeCOMPARE (Comparison of the everolimus
eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTÉ stent in
all-comers: a randomized open label trial). J Am Coll Cardiol. 2011;58:11–8.
38. Smits PC, Sheikjoesoef K, Royaards K-J, et al. Final Five Year Results From The
All-comer COMPARE Trial: A Prospective, Randomized Trial of Everolimus-
Eluting vs. Paclitaxel-Eluting Stents. J Am Coll Cardiol. 2013;62:B5–5.
39. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for
systematic reviews and meta-analyses: the PRISMA statement. Ann Intern
Med. 2009;151:264–9.
40. Palmerini T, Biondi-Zoccai G, Riva DD, et al. Stent thrombosis with
drug-eluting and bare-metal stents: evidence from a comprehensive
network meta-analysis. Lancet. 2012;379:1393–402.
41. Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions.
Wiley Online Library 2008.
42. Garg S, Serruys P, Onuma Y, et al. 3-Year Clinical Follow-Up of the XIENCE V
Everolimus-Eluting Coronary Stent System in the Treatment of Patients With
De Novo Coronary Artery LesionsThe SPIRIT II Trial (Clinical Evaluation of the
Xience V Everolimus Eluting Coronary Stent System in the Treatment of
Patients with de novo Native Coronary Artery Lesions). J Am Coll Cardiol
Intv. 2009;2:1190–8.
43. Gada H, Kirtane AJ, Newman W, et al. 5-Year Results of a Randomized
Comparison of XIENCE V Everolimus-Eluting and TAXUS Paclitaxel-Eluting
StentsFinal Results From the SPIRIT III Trial (Clinical Evaluation of the XIENCE V
Everolimus Eluting Coronary Stent System in the Treatment of Patients With De
Novo Native Coronary Artery Lesions). J Am Coll Cardiol Intv. 2013;6:1263–6.
44. Hermiller JB, Nikolsky E, Lansky AJ, et al. Clinical and angiographic outcomes of
elderly patients treated with everolimus-eluting versus paclitaxel-eluting stents:
three-year results from the SPIRIT III randomised trial. EuroIntervention.
2011;7:307–13.
45. Brener SJ, Kereiakes DJ, Simonton CA, et al. Everolimus-eluting stents in
patients undergoing percutaneous coronary intervention: Final 3-year results
of the Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent
System in the Treatment of Subjects With de Novo Native Coronary Artery
Lesions trial. Am Heart J. 2013;166:1035–42.
46. Onuma Y, Miquel-Hebert K, Serruys PW. Five-year long-term clinical
follow-up of the XIENCE V everolimus-eluting coronary stent system
in the treatment of patients with de novo coronary artery disease:
the SPIRIT II trial. EuroIntervention. 2013;8:1047–51.
47. Garg S, Serruys PW, Miquel‐Hebert K. Four‐year clinical follow‐up of the
XIENCE V everolimus‐eluting coronary stent system in the treatment of
patients with de novo coronary artery lesions: The SPIRIT II trial. Catheter
Cardiovasc Interv. 2011;77:1012–7.
48. Ng VG, Lansky AJ, Hermiller JB, et al. Three-Year Results of Safety and Efficacy
of the Everolimus-Eluting Coronary Stent in Women (from the SPIRIT III
Randomized Clinical Trial). Am J Cardiol. 2011;107:841–8.
49. Lansky AJ, Brar SS, Yaqub M, et al. Impact of routine angiographic follow-up
after percutaneous coronary intervention with drug-eluting stents in the
SPIRIT III randomized trial at three years. Am J Cardiol. 2012;110:21–9.
50. Almasood AS, Freixa X, Khan SQ et al. Stent Fracture after Everolimus-Eluting
Stent Implantation. Cardiol. Res. Pract. 2011;2011:1–5.
Meng et al. BMC Cardiovascular Disorders  (2016) 16:34 Page 11 of 11
